BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34403675)

  • 1. Structural and biochemical insights into a hyperthermostable urate oxidase from Thermobispora bispora for hyperuricemia and gout therapy.
    Chiu YC; Hsu TS; Huang CY; Hsu CH
    Int J Biol Macromol; 2021 Oct; 188():914-923. PubMed ID: 34403675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Elucidation of a Urate Oxidase from
    Chiu YC; Hsu TS; Huang CY; Hsu CH
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of a hyperthermostable AgUricase for hyperuricemia and gout therapy.
    Shi Y; Wang T; Zhou XE; Liu QF; Jiang Y; Xu HE
    Acta Pharmacol Sin; 2019 Oct; 40(10):1364-1372. PubMed ID: 31253939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
    Sherman MR; Saifer MG; Perez-Ruiz F
    Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
    Cammalleri L; Malaguarnera M
    Int J Med Sci; 2007 Mar; 4(2):83-93. PubMed ID: 17396159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
    Bomalaski JS; Clark MA
    Curr Rheumatol Rep; 2004 Jun; 6(3):240-7. PubMed ID: 15134605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catalysis and Structure of Zebrafish Urate Oxidase Provide Insights into the Origin of Hyperuricemia in Hominoids.
    Marchetti M; Liuzzi A; Fermi B; Corsini R; Folli C; Speranzini V; Gandolfi F; Bettati S; Ronda L; Cendron L; Berni R; Zanotti G; Percudani R
    Sci Rep; 2016 Dec; 6():38302. PubMed ID: 27922051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
    Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
    Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression, localization and metabolic function of "resurrected" human urate oxidase in human hepatocytes.
    Duan Y; Jiang N; Chen J; Chen J
    Int J Biol Macromol; 2021 Apr; 175():30-39. PubMed ID: 33513422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond.
    Schlesinger N
    Curr Rheumatol Rep; 2010 Apr; 12(2):130-4. PubMed ID: 20425022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gout: an overview of available urate lowering therapies].
    Richette P
    Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties.
    Nyborg AC; Ward C; Zacco A; Chacko B; Grinberg L; Geoghegan JC; Bean R; Wendeler M; Bartnik F; O'Connor E; Gruia F; Iyer V; Feng H; Roy V; Berge M; Miner JN; Wilson DM; Zhou D; Nicholson S; Wilker C; Wu CY; Wilson S; Jermutus L; Wu H; Owen DA; Osbourn J; Coats S; Baca M
    PLoS One; 2016; 11(12):e0167935. PubMed ID: 28002433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rasburicase (Fasturtec)].
    Vogt B; Gugger M; Frey FJ
    Ther Umsch; 2004 Sep; 61(9):579-82. PubMed ID: 15493120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGylation enhancement of pH stability of uricase via inhibitive tetramer dissociation.
    Tian H; Guo Y; Gao X; Yao W
    J Pharm Pharmacol; 2013 Jan; 65(1):53-63. PubMed ID: 23215688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urate oxidase (rasburicase) for treatment of severe acute gout: a case report.
    Wipfler-Freibmuth E; Dejaco C; Duftner C; Gaugg M; Kriessmayr-Lungkofler M; Schirmer M
    Clin Exp Rheumatol; 2009; 27(4):658-60. PubMed ID: 19772802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationalization design, soluble expression and PEG modification of highly active recombinant human-porcine uricase mutant protein.
    Tong M; Wang S; Luan J; Xie Q; Wang L; Shen X; Xiong S
    Int J Biol Macromol; 2024 Jun; 269(Pt 1):131989. PubMed ID: 38697425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
    Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
    J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent approaches to gout drug discovery: an update.
    Otani N; Ouchi M; Kudo H; Tsuruoka S; Hisatome I; Anzai N
    Expert Opin Drug Discov; 2020 Aug; 15(8):943-954. PubMed ID: 32329387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Directed evolution to improve the catalytic efficiency of urate oxidase from Bacillus subtilis.
    Li W; Xu S; Zhang B; Zhu Y; Hua Y; Kong X; Sun L; Hong J
    PLoS One; 2017; 12(5):e0177877. PubMed ID: 28531234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arxula adeninivorans recombinant urate oxidase and its application in the production of food with low uric acid content.
    Trautwein-Schult A; Jankowska D; Cordes A; Hoferichter P; Klein C; Matros A; Mock HP; Baronian K; Bode R; Kunze G
    J Mol Microbiol Biotechnol; 2013; 23(6):418-30. PubMed ID: 24022585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.